Skip to main content
Premium Trial:

Request an Annual Quote

ApoCell Lands Summit Investment

NEW YORK (GenomeWeb News) – Biomarker technology developer ApoCell has received an investment from Boston-based equity investor Summit Partners, which supports life sciences companies.

The amount of the investment was not disclosed.

ApoCell, which spun out from the University of Texas MD Anderson Cancer Center in 2005 and operates out of Houston, will use the funds to continue developing its technology platforms aimed at using biomarker signatures in oncology, diabetes, molecular diagnostics, and drug development.

Summit said that the ApoCell technology can support the analysis and specimen logistics for preclinical to Phase III trials and other similar projects.

Tom Jennings, managing director with Summit Partners, will join ApoCell's board of directors.

The Scan

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.